We can’t show the full text here under this license. Use the link below to read it at the source.
Fixed versus flexible combination of GLP‐1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study
Comparing fixed and flexible combinations of GLP-1 drugs with basal insulin in type 2 diabetes
AI simplified
Abstract
A total of 609 patients were included in the study, showing HbA1c reductions of 0.6% for the flexible group and 0.8% for the fixed group after 5.7 months.
- Both fixed and flexible combinations of basal insulin and GLP-1 receptor agonists resulted in similar reductions in HbA1c levels.
- Body weight decreased by 2.8 kg in the flexible group compared to a 1.2 kg reduction in the fixed group.
- After adjusting for confounding factors, the flexible combination showed a significantly greater reduction in body weight.
- Higher final doses of basal insulin were used in the fixed group, while the flexible group had higher doses of GLP-1 receptor agonists.
- Sensitivity analyses generally supported the main findings, except multivariable adjustments indicated a greater HbA1c reduction in the fixed group.
AI simplified
Key numbers
2.5 kg
Body Weight Reduction
Body weight decreased by 2.5 kg in the flexible group vs. 1.2 kg in the fixed group.
0.8%
HbA1c Change
HbA1c declined by 0.8% in the fixed group vs. 0.6% in the flexible group.
878.8 €
Treatment Cost
Average treatment cost was 878.8 €/patient for fixed vs. 1096.0 €/patient for flexible.